Plain-English translation of NCT07148739 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
The ENACT Study is looking at how people with cystic fibrosis respond to triple combination CFTR modulator therapy — a newer class of medications that help CF patients. The researchers want to understand why some patients have side effects while others don't, and whether adjusting doses could help people tolerate the medication better while keeping it effective.
Currently, doctors prescribe the same doses of this medication to all CF patients, but people respond very differently. By studying how the medication works in individual bodies and what side effects occur, researchers hope to eventually predict who will benefit most from treatment and who might need a different dose — avoiding unnecessary side effects and cost for people who won't benefit.
You likely qualify if…
You likely don't qualify if…
This is primarily an observational study, meaning you won't be asked to take a new medication — just participate in visits to help researchers understand how your current CF medication is working. You may have a single visit where blood samples are taken to measure medication levels and check for side effects. If you're experiencing side effects, you may be invited to participate in an additional study where doctors will work with you to adjust your dose to find a better balance, and then monitor you to see if side effects improve.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States